Dimension Therapeutics, Inc., a gene therapy platform company, focuses on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression in patients with hemophilia B; DTX201, a gene therapy program for the treatment of hemophilia A; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; and DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase. Dimension Therapeutics, Inc. was founded in 2013 and is based Cambridge, Massachusetts.
http://www.priceseries.com/trade/DMTX-Dimension-Therapeutics-Inc-stock-gains-95-percent-a-Trade-Record-by-priceSeries-2017082920171025.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments